Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker

Research output: Contribution to journalArticlepeer-review

Abstract

The pro-inflammatory cytokine tumor necrosis factor-α (TNF-α) plays a central role in mucosal inflammation and is a key mediator in the inflammatory cascade in both Crohn's disease (CD) and ulcerative colitis (UC). Infliximab, a monoclonal antibody against TNF-α has been proved highly effective in the clinical management of both forms of IBD. Aim of this paper is to review the mechanisms of action of infliximab in IBD.

Original languageEnglish
JournalDigestive and Liver Disease
Volume40
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Jul 2008

Keywords

  • Crohn's disease
  • Inflammatory bowel disease
  • Infliximab
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker'. Together they form a unique fingerprint.

Cite this